Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Chronic Myeloid Leukemia News
CHRONIC MYELOID LEUKEMIA ADVISOR
Chronic Myeloid Leukemia News
CML: COVID-19 May Be Fatal in More Than 5% of Patients
The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.
Response-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic Myeloid Leukemia
A 45-mg starting dose, reduced to 15 mg, produced the best outcome.
Chronic Myeloid Leukemia: What Your Patients Need to Know
Chronic myeloid leukemia (CML) can be painful and life-threatening if it is not caught in time. How can you educate patients with symptoms or who are newly diagnosed about the detection, symptoms, risk factors, and treatment of CML?
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
How Intermittent Fasting Affects Patients Receiving Tyrosine Kinase Inhibitors for CML
Researchers sought to determine the effects of fasting on drug absorption and efficacy in patients receiving TKIs for chronic myeloid leukemia.
Dasatinib, Nilotinib Effective Second-Line Therapy for Chronic Myeloid Leukemia
Researchers sought to determine whether dasatinib and nilotinib would be effective second-line therapies for patients with chronic phase CML.
BCR-ABL1 Kinetics Associated With Long-Term TFR Status in Patients With Chronic Myeloid Leukemia
Researchers sought to determine key determinants of sustained treatment-free remission in patients with CML who have completed TKI treatment in an attempt to develop strategies that achieve long-term remission.
Case Study Shows Potential Protective Effect of TKI Therapy for Chronic Myeloid Leukemia
A case study with a literature review demonstrates potential antiviral effect of TKI therapy in patients with cancer and COVID-19.
Molecular Response Maintained With Intermittent Tyrosine Kinase Inhibitor Regimen in Patients With CML
Results of the ongoing OPTkIMA study comparing a fixed and a progressive TKI plan in patients with CML is discussed.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Anti-Emetic Drug Effectively Blocks CD93 Signaling in Preclinical Evaluations, Suggesting Suitability in CML
Investigators assessed the activity of the anti-emetic agent metoclopramide in murine models.
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Iclusig Approved for Resistant or Intolerant Chronic-Phase CML
The sNDA approval is based on efficacy and safety data from the open-label phase 2 OPTIC trial and 5-year data from the phase 2 PACE trial.
AI-Based Model Made Optimal Selections of Frontline TKI Therapy in CML
Investigators report on outcomes for patients with chronic phase CML whose treatment was determined using an artificial intelligence-based model.
STAMP Inhibitor May Be a New Treatment Option in CML
Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).
Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Study results suggested that the discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia may be safe, without limiting remission.
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
British Society for Haematology Guideline Update for the Diagnosis and Management of Chronic Myeloid Leukemia
The British Society for Haematology has published updated guidelines for the diagnosis and management of chronic myeloid leukemia in adults and children.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...